Recombinant Antibodies against Mycolactone by Naranjo, Leslie et al.
HAL Id: hal-02323359
https://hal.archives-ouvertes.fr/hal-02323359
Submitted on 18 Dec 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
Recombinant Antibodies against Mycolactone
Leslie Naranjo, Fortunato Ferrara, Nicolas Blanchard, Caroline Demangel,
Sara D’angelo, M. Frank Erasmus, Andre Teixera, Andrew R.M. Bradbury
To cite this version:
Leslie Naranjo, Fortunato Ferrara, Nicolas Blanchard, Caroline Demangel, Sara D’angelo, et al..
Recombinant Antibodies against Mycolactone. Toxins, MDPI, 2019, 11 (6), pp.346. ￿10.3390/tox-
ins11060346￿. ￿hal-02323359￿
toxins
Communication
Recombinant Antibodies against Mycolactone
Leslie Naranjo 1,†, Fortunato Ferrara 1,†, Nicolas Blanchard 2 , Caroline Demangel 3 ,
Sara D’Angelo 1, M. Frank Erasmus 1, Andre A. Teixeira 1,4 and Andrew R.M. Bradbury 1,*
1 Specifica Inc., Santa Fe, NM 87505, USA; lnaranjo@specifica.bio (L.N.); fferrara@specifica.bio (F.F.);
sdangelo@specifica.bio (S.D.); ferasmus@specifica.bio (M.F.E.); ateixeira@specifica.bio (A.A.T.)
2 Université de Haute-Alsace, Université de Strasbourg, CNRS, LIMA, UMR 7042, 68000 Mulhouse, France;
n.blanchard@unistra.fr
3 Immunobiology of Infection Unit, Institut Pasteur, INSERM U1221, 75011 Paris, France;
caroline.demangel@pasteur.fr
4 New Mexico Consortium, Los Alamos, NM 87544, USA
* Correspondence: abradbury@specifica.bio; Tel.: +1-505-431-0065
† These authors contributed equally to this work.
Received: 28 March 2019; Accepted: 13 June 2019; Published: 17 June 2019


Abstract: In the past, it has proved challenging to generate antibodies against mycolactone, the
primary lipidic toxin A of Mycobacterium ulcerans causing Buruli ulcer, due to its immunosuppressive
properties. Here we show that in vitro display, comprising both phage and yeast display, can be
used to select antibodies recognizing mycolactone from a large human naïve phage antibody library.
Ten different antibodies were isolated, and hundreds more identified by next generation sequencing.
These results indicate the value of in vitro display methods to generate antibodies against difficult
antigenic targets such as toxins, which cannot be used for immunization unless inactivated by
structural modification. The possibility to easily generate anti-mycolactone antibodies is an exciting
prospect for the development of rapid and simple diagnostic/detection methods.
Keywords: mycolactone; Buruli ulcer; recombinant antibody; phage display; yeast display; single
chain Fv
Key Contribution: The demonstration that recombinant display methods can be used to select
antibodies against small hydrophobic toxins, such as mycolactone.
1. Introduction
Buruli ulcer (BU) is a disfiguring and debilitating neglected tropical disease caused by
Mycobacterium ulcerans, a slow-growing organism that produces mycolactone, a unique lipidic toxin
essential to the pathogenesis of BU [1–6], and unique to M. ulcerans. In addition to causing skin necrosis,
mycolactone causes cytotoxicity and immunosuppression [5,7–12], which may prevent M. ulcerans
clearance by the host. Mycolactone exerts its toxicity by inhibiting the translocation of secretory and
membrane proteins across the ER membrane, by inhibiting the heterotrimeric Sec61 complex [13].
Interestingly, the ex vivo cytotoxic potency of mycolactone in biopsies from BU lesions appears to
be greater than that of corresponding amounts of purified mycolactone, suggesting that in vivo the
toxin exists in biological complexes that exacerbate its toxicity. BU continues to develop in West
Africa [14,15], Australia [16,17], and other areas [18,19]. Transmission is presumed to involve cutaneous
inoculation through skin injuries and/or insect bites [17,20]. The disease begins as a painless nodule or
plaque, which subsequently ulcerates and grows inexorably, eventually threatening limbs and causing
functional disabilities, often resulting in permanent social, economic, and developmental problems.
The mortality rate of BU is low and usually related to untreated cases [21]. Ulcers are characteristically
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painless and may lead to bacterial super-infection and sepsis. Even appropriately treated large ulcers
spanning joints often heal with disabling scarring and limb contracture [22].
Until 2004, treatment of BU consisted of wide surgical excision and skin grafting. At that time
the WHO [23] first recommended therapy with rifampin and streptomycin, based on pioneering
studies in the mouse footpad model [24–26] and confirmed by subsequent clinical experience [27,28].
Early implementation of this pharmaceutical approach eliminates the need for surgery and its
disabling sequelae, making early diagnosis crucial. However, no rapid, simple, specific, non-invasive
point-of-care (POC) diagnostic test exists. Available tests, including microscopy, culture, PCR [29],
fluorescent thin layer chromatography [30] and the histopathology of lesions all require relatively
sophisticated laboratory facilities and expertise [31]. The problem is aggravated by the complex
differential diagnosis, which depends upon the clinical presentation (ulcer or nodule), and
geographical localization.
Most POC diagnostics, particularly lateral flow assays [32], rely on antibodies as detection
agents. However, given the cytotoxicity and immunosuppressive effects of mycolactone [5,7–12],
the generation of antibodies by traditional immunization has, until recently [33], been extremely
challenging. This problem was overcome by immunizing with a truncated synthetic non-toxic
variant [33], leading to the derivation of a number of murine monoclonal antibodies showing in vitro
neutralization activity. In humans, subjects with active disease show strong humoral reactions to
some M. ulcerans proteins [34], including culture filtrate proteins [35], but with high cross-reactivity to
antigens from other mycobacterial species [34], with up to 37% of control subjects showing positive
antibody responses [35,36]. No systematic study investigating the antibody response to the toxin
appears to have been published.
An alternative to the use of traditional immunization to generate antibodies has been the use
of in vitro display methods [37] to select antibodies from large naïve or immune libraries. In these
techniques, large antibody libraries in either the Fab or single chain Fv (scFv) format [38] are displayed
on the surface of filamentous phage [39,40] or yeast [41,42], and antibodies binding targets of interest
are purified away from the multitude of non-binding antibodies. Targets are usually immobilized and
the binding antibodies separated from non-binding antibodies by a series of washing steps, followed by
elution. The selection of antibodies from vast antibody libraries, instead of using animal immunization
and hybridoma technology, offers the advantage of guiding the selection process towards antibodies
with rare specificities, epitopes or characteristics that are extremely difficult to find with animal-based
methods. The key feature of in vitro display systems is that phenotype (the displayed antibody) and
genotype (the gene encoding the displayed antibody) are coupled in such a way that selection of an
antibody on the basis of its binding activity leads to simultaneous selection of the gene that encodes it.
This guarantees the permanent availability of selected clones over time, by virtue of gene synthesis,
and also makes it possible to express clones in different antibody formats (e.g., with Fc domains from
different species), as well as improve antibody properties, such as affinity. Furthermore, recombinantly
expressed antibodies have been shown to be more specific than their hybridoma expressed counterparts,
which often express additional immunoglobulin chains that detract from their specificity [43].
In general, the larger the library, the higher the affinity of antibodies that can be selected, although
this tends to be target specific, with protein targets generally yielding much higher affinities than small
targets such as mycolactone. We developed a recombinatorial method [44,45] to create particularly
large phage antibody libraries, from which human antibodies against a number of challenging targets
have been generated [46–48]. Here we describe the application of this approach to select human
antibodies recognizing mycolactone.
The aim of the present study was to generate a set of human antibodies, specifically recognizing
mycolactone, that could potentially provide a set of novel molecular tools for the study, diagnosis,
prophylaxis, and potential treatment of BU.
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2. Results
2.1. Antibody Selection
The general strategy used to generate recombinant antibodies against a challenging target such as
mycolactone has been summarized in the schematic diagram shown in Figure 1.
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Figure 1. Strategy used to select antibodies using both phage and yeast display. Antibodies are first
selected against mycolactone using two rounds of phage display, after which the whole selection output
is cloned into a yeast display vector. A further one or two rounds of sorting by flow cytometry allow
the subsequent isolation and testing of single clones, followed by affinity maturation by mutagenesis
to select for higher affinity binders. The fi al selected antibodies are finally expressed as ‘scFv-Fc
fusions’—where the variabl domain of the antibody (scFv) is fused with the CH2-CH3 constant region
(Fc) of human immunoglobulin IgG1—and further validated in an enzymatic assay (ELISA) for its
specific binding o the toxin of interest.
Biotinylated mycolactone was used to sel ct antibodies from a large l t rized phage
single chain Fv (scFv) antibody libra y [44, 9] using a combination of east display, which
combines the adv ntages of phage display (selection from extremely large libraries) with those of yeast
display (precise selection calibration by flow cytometry) [46,50]. Figure 2 shows the representative flow
cytometry plots of selection outputs, in which after phage were selected using an excess of biotinylated
mycolactone, the enriched antibodies were subcloned into the yeast display format and sorted at 1 µM
for 1–2 rounds. Each dot represents an individual yeast organism displaying 30,000–100,000 copies
of a single antibody. The x-axis shows the level of antibody displayed on the surface of the yeast, as
recognized by a fluorescently labeled antibody specific to the SV5 tag [51,52], fused in frame with the
displayed single chain Fv antibodies. The y-axis shows the amount of bound biotinylated mycolactone,
detected using fluorescently labeled streptavidin, with greater binding indicated by increased values
on the y-axis. Yeast displaying desirable antibodies are to be found in the upper right quadrant,
representing those that display antibodies and bind to mycolactone. Those found in the lower left
quadrant represent daughter cells known to lose antibody display immediately after cell division.
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Figure 2. Analysis of the flow cytometric output of scFv selections displayed on the surface of yeast.
Selection 1 was carried out using plastic containers, while Selection 2 was carried out using glass
containers. For Selection 2 the enrichment progress during the sorting steps is shown, including the
gates used for the sorting of binding cells. The populations labeled as “no mycolactone” show the
background binding for the fluorescently conjugated streptavidin.
In a first selection attempt (Selection 1, Figure 2), the phage antibody library was incubated with
5 µM biotinylated mycolactone and selection was carried out using streptavidin coated magnetic
beads and an automated system (Kingfisher System, Thermo Fisher Scientific, Waltham, MA, USA).
When 96 individual yeast clones were isolated, and their V gene sequenced, clone M3_B11 (Table 1) was
the only clone found. We concluded that this result may have been due to the known hydrophobicity
of mycolactone, and the fact that the Kingfisher system uses plastic containers to carry out selections,
with probably most of the mycolactone adsorbed to the plastic surface and not available for selection.
Consequently, a second selection (Selection 2, Figure 2) was carried out manually in glass vials (Agilent
Technologies, Santa Clara, CA, USA) using 500 nM of biotinylated mycolactone in each phage selection
round, and subsequently following the same approach by subcloning the phage selection output into
the yeast display vector and carrying out the sorting steps using 1 µM antigen. During the sorting
process two populations were noticeable after the first enrichment step with noticeably different
affinities for the binders. When setting the gate for the sorting we included both of these populations.
In this case, when 96 single yeast clones were isolated and sequenced we were able to recover a total of
10 different antibodies, including the only one selected in the previous selection campaign. Table 1
illustrates the 10 different antibodies, with two antibodies (M3_A10 and M3_B11) differing by only a
single amino acid, and two others (M3_B10 and M3_B12) differing only in the HCDR3s. All the different
clones were tested for binding to mycolactone by flow cytometry at two concentrations (240 nM and
80 nM), and shown to bind mycolactone (Figure 3), albeit with poor affinities, with the majority of the
clones estimated to have Kds >1 µM.
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Table 1. Complementarity determining regions (CDRs) of different mycolactone specific antibodies
identified by phage and yeast display using the two selection strategies described in the text.
Clone ID LCDR3 HCDR1 HCDR2 HCDR3
Abundance
after
Selection 1
Abundance
after
Selection 2
M3_B11 MQARQTPPT GGTFSSYA IIPIFGTA ARVRWEPQSGYYHGMDVW 100% 18%
M3_A10 MQARQTPPT GGTFSSYA IIPIFGTA ARVRWVPQSGYYHGMDVW 0% 30%
M3_E1 AAWDDSLNGPA GYTFTSYG YTFTSYG ARVGGMGGDYVEYW 0% 20%
M3_B12 SSYSSSSSYV GGTFSSYA IIPIFGTA LIVGATTGGDAFDIW 0% 16%
M3_B4 LLYYGGDWV GGTFSSYA IIPIFGTA AAVGLDAFDIW 0% 4%
M3_C6 MQGTHWPPT GGTFSSYA IIPIFGTA AITDGIFDIW 0% 4%
M3_A2 AAWDDRLNGVV GGTFSSYA IIPIFGTA ARGSGYYDSSGYHWYFDLW 0% 2%
M3_C11 SSYAGSNGSV GGTFSSYA IIPIFGTA AVYSSGWYGGTTEDYW 0% 2%
M3_E9 MQGTHWPPT GGTFSSYA IIPIFGTA ARVAYYYGSGSYSFDYW 0% 2%
M3_B10 SSYSSSSSYV GGTFSSYA IIPIFGTA AAADYYDSSGYYYGGVEEHW 0% 2%
Figure 3. Binding profile analysis by Flow cytometry of individual selected scFvs tested against 240
and 80 nM mycolactone and a negative control. M3_B11 was the only clone identified in Selection 1
and among the 10 identified after Selection 2.
2.2. Affinity Maturation
The clone M3_B11, which was found after the first selection effort—Selection 1—was initially
taken forwards for further analysis and affinity maturation. We tried to improve the binding activity by
introducing random mutations by error prone PCR (ePCR) [53]. A population of mutated clones was
obtained and displayed on yeast, and subsequently enriched for improved affinity using four steps of
fluorescence activated cell sorting. Eventually, 96 affinity matured clones were picked, sequenced and
tested, and 6 different mutated clones were isolated by Sanger sequencing. Table 2 shows the sequences
of improved clones and their affinities as measured on the yeast surface. Among the matured variants,
one was found to be identical to M3_A10, selected independently using the Selection 2 approach.
By carrying out antigen titrations on these antibodies displayed directly on the yeast surface and
assessing the mean fluorescence intensity of the yeast populations it was possible to calculate antibody
affinities [54], which ranged from 145 nM to 470 nM. These clones were recloned into a yeast secretion
vector for expression as scFv fused to the Fc domain of IgG1 immunoglobulin and tested for binding to
mycolactone in an ELISA format, thanks to the presence of the Fc portion (CH2-CH3 domains of a
human IgG1) that is detectable with commonly available secondary anti-human IgG reagents [50]. The
ELISA results in Figure 4 are directly comparable to the affinities listed in Table 2: the parental clone,
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the one with the worse affinity, was characterized by a lower detection activity, while the improved
clones performed better in the assay. The ELISA signals obtained from non-affinity matured clones
that showed a binding profile on yeast similar to that of the parental antibody M3_B11, were similarly
low or even worse (data not shown).
Table 2. Sequences of the complementarity determining regions (CDRs) of different affinity matured
mycolactone specific antibodies identified by yeast display after error prone PCR. CI represents the
confidence interval.
Clone ID HCDR1 HCDR2 HCDR3
Percentage Sequence Abundance
Yeast-Based
Affinity CISelection
Output
2 rds
Affinity
Maturation
4 rds
Affinity
Maturation
parental GGTFSSYA IIPIFGTA ARVRWEPQSGYYHGMDVW 91% 17% 470 nM 241–720
AM_1 GGTFSSYA IIPIFGTA ARVRWEPRSGYYHGMDVW 10% 360 nM 260–450
AM_2 GGTFSSYA IIPIFGTA ARVRWVPRSGYYHGMDVW 7% 345 nM 181–676
AM_3/
M3_A10 GGTFSSYA IIPIFGTA ARVRWVPQSGYYHGMDVW 10% 20% 149 nM 71–271
AM_4 GGAFSRYA IIPIFGTA ARVRWVPQSGYYHGMDVW 29% 54% 145 nM 69–298
AM_5 GGTFSRYA IVPIFGTA ARVRWVPQSGYYHGMDVW 24% 16% 212 nM 159–324
Figure 4. Detection activity of the scFv-Fc derived from individual affinity matured scFvs tested by
ELISA against 300 nM biotinylated mycolactone. Ubiquitin (300 nM) was used as negative control
antigen and an anti-ubiquitin scFv-Fc derived from the same library was used as an assay positive
control. * Indicate a p value < 0.05 compared to the parental clone.
We performed an additional ELISA assay to ascertain whether the antibodies were able to bind to
mycolactone that was not biotinylated. The results showed a very similar pattern to those obtained
previously using biotinylated antigens (Figure 5). Antibodies also showed no binding to ubiquitin or
LPS, used as negative controls, and directly coated to the ELISA plate.
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Figure 5. Detection activity of the scFv-Fc derived from individual affinity matured scFvs tested by
ELISA against 300 nM of non-biotinylate mycolact ne. Ubiquitin and LPS (300 nM) were used as
negative control antigens and an anti-ubiquitin scFv-Fc derived from the same library was us d as an
assay positive control.
2.3. Next Generation Sequencing (NGS) Analysis
Due to the relatively low number of identified binders obtained by traditional screening, we
wanted to assess the entire diversity of the mycolactone-binding population displayed on yeast by
NGS. We focused our analysis on the third heavy chain complementary determining region (HCDR3),
which is generally considered to be the most important determinant of antibody binding, due to its
position in the center of the antibody paratope, and its enormous diversity, compared to the other
complementarity determining regions.
We analyzed approximately 200,000 reads from MiSeq sequencing on the sorted output, which
revealed 666 different HCDR3 sequences. For a better understanding of the effective functional diversity
of these CDRs we calculated the Levenshtein distance between these HCDR3 amino acid sequences and
applied a principal component analysis for visualization (Figure 6A). The plot revealed the presence of
at least two regions of high density, suggesting clusters of HCDR3s. We then used a greedy iterative
clustering method to group the HCDR3 amino acid sequences. We found 34 clusters containing more
than one different HCDR3, plus 157 additional HCDR3s that did not cluster with any other sequences
(Table S1). Interestingly, a large diversity was found in clusters 0 and 5, containing 115 and 231 different
HCDR3 sequences, respectively (Figure 6B,C). Other clusters also showed modest diversity, such as
cluster 1, 2, 3, 4, with 16, 35, 22, and 7 different sequences respectively. The functionality of these
groups of clones remains untapped, since by random colony screening we have found and tested
clones from just a few of them (0, 1, 2, 3, 4, 5, 13, and 14), leaving a large space for the exploration and
development of new anti-mycolactone antibodies.
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Figure 6. (A) Plot of anti-mycolactone HCDR3 antibody sequences plotted against the percentage
abundance (y-axis). The bubble sizes are proportional to the number of different HCD3 sequences
present in each cluster. (B) Plot of the first two components of the principal component analysis (PCA)
performed using the Levenshtein distance of the HCDR3 amino acid sequences of sorted antibodies
recognizing mycolactone. Different colors represent different clusters of HCDR3 identified. Clones
represented as crosses did not cluster with any other sequence. (C) Clonotypic analysis of individual
clusters showing the variability in each position of the HCDR3 sequence. The consensus sequences are
generated from alignment of all HCDR3 sequences belonging to a given cluster. In some cases, there
are a few HCDR3 sequences that contains additional amino-acids not present in most other sequences
resulting in apparent ‘gaps’ in the consensus sequences.
3. Discussion
In the present work, we describe an approach to generate recombinant human anti-mycolactone
antibodies that is complementary to the one implemented by Dangy et al., [33], who showed that highly
specific, monoclonal antibodies could be generated by immunization of mice using synthetic truncated
mycolactone coupled to BSA as an immunogen. These murine antibodies demonstrated varying
degrees of in vitro mycolactone neutralization, which in the best case prevented cellular apoptosis at
an antibody:toxin molar ratio of 2.5:1. These results illustrate the potential of synthetic mycolactone
derivatives to act as vaccines to prevent Buruli ulcer, and the possibility of developing new tools for
research, diagnosis, prevention, and control of Buruli ulcer. The neutralizing antibodies obtained by
Dangy et al. have the limitation of being derived from hybridomas, making them suboptimal for the
treatment of human subjects, due to the possibility of anti-murine antibody responses [55]. Although it
is feasible to obtain humanized derivatives of these murine antibodies to potentially treat Buruli ulcer,
such strategy can be time consuming and does not always guarantee that the ‘converted’ antibodies
will retain the same efficacy or might still trigger an immunogenic reaction [56,57]. For this reason,
human antibodies, obtained from in vitro antibody libraries can provide a potentially better option for
the treatment of Buruli ulcer, either by systemic or local administration.
Toxins 2019, 11, 346 9 of 15
In this publication, we demonstrate the preliminary generation of human recombinant antibodies
recognizing mycolactone by direct selection on biotinylated complete mycolactone from a large naïve
natural human antibody library. This result reinforces the value of in vitro display methods to select
antibodies against toxic molecules that can be more difficult to use in traditional immunization. A
first attempt (Selection 1) to isolate antibodies against mycolactone resulted in only a single clone;
we speculated that this result was due to the very hydrophobic nature of mycolactone: even if some
phage bind the molecule, its strong interaction with the plastic surface makes the rescue of bound
phage during the selection step extremely difficult. When glass vials were implemented (Selection 2)
we were able to rescue a total of 10 different antibodies, including the one already identified after the
‘plastic-based’ selections. Interestingly the only clone identified during the Selection 1 attempt, was the
third most abundant clone (18%) of the final enriched population obtained by the Selection 2 approach,
while the most abundant clone (30%) differed by only one amino acid (V instead of E) in the HCDR3.
In general, the affinities of the selected antibodies were poor, especially when compared with those
obtained against protein antigens from the same library (ranging from 2 to 100 nM), a finding that is
consistent with results obtained against peptide and other small molecule targets [47].
For this reason, we tried to improve the affinity of the first identified clone binding mycolactone,
found in Selection 1, by using error-prone PCR, and were able to obtain modest improvements.
Interestingly, the sequences of the two best clones (~3-fold affinity improvement) were found to be
identical to the best binder M3_A10 obtained after Selection 2, and closely related to M3_A10 differing
by two additional amino acids in HCDR1.
The affinity maturation effort indicates the need to implement more sophisticated approaches,
such as targeted CDR mutations [58] on the higher affinity antibodies already obtained. With further
affinity maturation, it is expected that the affinities of these antibodies could be significantly improved,
allowing their possible use in point of care diagnostic assays, perhaps in combination with those
antibodies recently developed by traditional approaches [33].
Because of the traditional screening approach of picking random clones, sequencing and testing
them might limit our capacity to identify all the potential binders selected during our campaigns
against mycolactone. We implemented next generation sequencing (NGS) to allow a far deeper
examination of the antibodies present in a selection output. The analysis was centered on the
third heavy chain complementary determining region (HCDR3), generally considered to be the
most important determinant of antibody binding, due to its position in the center of the antibody
paratope [59], and its enormous diversity [60,61], compared to the other complementarity determining
regions. Although a particular HCDR3 sequence does not necessarily predict specific binding [62],
HCDR3 diversity is sufficiently great that it can be considered a ‘fingerprint’, and used to identify
antibody clonotypes likely to bind to the target similarly. When we sequenced the entire selected
antibody pool after Selection 2 by NGS, we found that a number of different clonotypes were present,
and that our initial screening approach was only able to identify the most abundant ones, suggesting
that a larger number of potential binders, possibly recognizing different regions of the mycolactone
molecule, can be rescued from our selection attempts. We plan to rescue some of these different
antibodies and test them against previously described synthetic mycolactone derivatives [33], to see
whether they are able to compete with the murine monoclonal antibodies, or recognize alternative
epitopes. Such a plethora of novel mycolactone antibodies represent the first important step towards
the generation of rapid and robust diagnostic assays, where different antibodies recognizing different
epitopes can guarantee better sensitivity and specificity.
4. Materials and Methods
4.1. Biotinylated Mycolactone
Biotinylated mycolactone was produced according to a modification of the protocol reported by
Chany et al. [63]. To synthetic mycolactone A/B provided by Pr. Y. Kishi (1 mg, 1.35 µmol), a 0.01 M
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solution of NaIO4 (0.269 mL, 2.69 µmol) was added in a 1:1 mixture of THF/H2O (0.5 mL). The reaction
was stirred and protected from light at room temperature for 1.5 h. Then, the reaction mixture was
quenched by the addition of a 1 M aqueous Na2S2O3 solution and diluted with EtOAc. The organic
layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude
residue was resuspended in MeOH (167 µL) before the addition of (+)-biotinamidohexanoic acid
hydrazide (1.5 mg, 4.04 µmol) dissolved in DMSO (167 µL). The resulting mixture was stirred and
protected from light at room temperature for 24 h. The reaction was then partitioned between water
and EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and
concentrated. The crude residue was purified by preparative TLC (elution with AcOEt/MeOH 8:2)
to give biotinylated mycolactone (1.2 mg, 89%) and the corresponding sulfoxide (0.4 mg, 11%) as a
yellowish oil and as a mixture of isomers that was not separated (E-∆4’-5’/Z-∆4’-5’ 1:1).
Determination of HPLC purity: Purity > 95% of biotinylated mycolactone was determined
by HPLC (analytical C18 column (Eclipse XDB-C18), 3.5 µm, 3.1 × 30 mm, sample concentration:
0.2 mg/mL in CH3CN/H2O, injection: 5 µL, eluent: CH3CN/H2O 60:40 to 100:0, flow: 0.3 mL/min).
LCMS tR-(biotinylated mycolactone) = 4.790 min, m/z 503.9 ([M + 2H]2+); tR-(biotinylated
mycolactone-sulfoxide) = 2.704 min, m/z 511.9 ([M + 2H]2+).
4.2. Phage Display Selections
The first selection was carried out using the automated Kingfisher magnetic bead system [64]
(Thermo Lab Systems), using a large naive phage display antibody library [44]. The library was obtained
from 40 healthy donors by amplifying the V genes from the IgM B-cell pool, resulting in a collection of
antibody fragments from a source of genes that is not biased toward specific antigens, but useful for
selecting antibodies against all possible types of antigen structures. A measure of 5 µM of biotinylated
mycolactone was used in each selection cycle, where the biotinylated mycolactone was incubated with
the phage antibody library and the bound phages were captured using 2 × 107 streptavidin-conjugated
magnetic beads (Dynabeads M-280). After removal of the non-binding phage, the remaining phage
particles were recovered from the beads by acid elution and used to infect F’ pilus-carrying bacteria
(Ominmax-2T1, Thermo Fisher Scientific, Waltham, MA, USA). The phages were propagated and the
selection cycle reiterated. Three rounds were performed in this selection. In a second phage selection,
two rounds of phage selection were performed manually in screw top amber glass vials (Agilent
Technologies) using the same technique described above with 500nM of biotinylated mycolactone in
each selection round.
4.3. Yeast Display and Sorting of scFvs
After phage selection, the output of scFv clones were PCR amplified with specific primers
introducing an overlapping region with the yeast display vector pDNL6 [46,50]. The vector and the
amplification products were co-transformed into competent yeast cells to allow cloning by homologous
recombination [65]. The yeast mini-libraries were further enriched for target-specific binders by
applying two rounds of flow cytometry sorting (FACSAria, Becton Dickinson, San Jose, CA, USA), as
described [65]. After induction, 2 × 106 yeast cells were incubated with 1uM biotinylated mycolactone
(first selection) and 500nM (second selection). Cells were labeled with streptavidin-Alexa-Fluor 633 to
detect binding of biotinylated target antigens and anti-SV5-PE to assess scFv display levels. In the
second sort, neutravidin-Alexa-Fluor 633 was used to replace conjugated streptavidin and eliminate
the chance of sorting streptavidin binders. Yeast clones showing both antigen binding (Alexa-Fluor
633 positives) and display (PE positives) were sorted. The collected cells were grown at 30 ◦C for
2 days and induced for the next round of sorting at 20 ◦C for 16 h.
Final sorted outputs from both selections were transformed into bacteria (Ominmax-2T1) and
plated for single colony isolation. Clones were picked from each selection and analyzed by Sanger
sequence analysis, which provides the full-length sequence of the scFv clones and can determine the
diversity of the enriched antibodies. In fact, the clones were determined to be unique based on the
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HCDR3 amino acid sequence. The first selection contained only one unique clone which was used as
the template for affinity maturation. Unique clones identified from the second selection were expressed
on yeast and affinity measurements were carried out by using the antibody displayed on the yeast and
flow cytometry, according to published methods [66]. The output from the second selection was PCR
amplified, gel purified, and prepared for next generation sequence analysis. All the described flow
cytometry experiments were performed using the FACSAria (Becton Dickinson).
4.4. Affinity Maturation
Four rounds of affinity maturation using error prone PCR and yeast sorting were performed [67].
Decreasing biotinylated mycolatone concentrations were used between affinity maturation rounds
(1 uM, 500 nM, 250 nM, and 125 nM). The parental clone, identified in the first selection, was used as the
starting template for error prone PCR. The yeast expression vector and the error prone amplification
product were co-transformed into competent yeast cells to allow cloning by homologous recombination,
described above. Using flow cytometry individual yeast cells with positive mycolactone binding signal
and scFv display were sorted, propagated, and subsequently used as template for additional affinity
maturation rounds. The output from each affinity maturation round was analyzed by flow cytometry
and the streptavidin-Alexa-Fluor 633 mean fluorescent value (mycolactone binding) were measured.
The second and final affinity maturation rounds were transformed into bacteria (Ominmax-2T1), plated
for single colony isolation, and analyzed by Sanger sequence analysis. Unique clones were determined
by the full-length heavy chain amino acid sequence. Representative clones were expressed on yeast,
affinity measurements calculated, and monoclonal antibodies produced.
4.5. Production of Monoclonal Antibodies (Yeast)
Unique clones were subcloned into the yeast expression vector pDNL9-HMR (Human Minibody
for Recombination) to allow the expression and secretion of scFvs as human Fc fusions [68] into the
culture supernatant. pDNL6 and pDNL9-HMR were designed to have compatible ends to promote
in vivo homologous recombination of the PCR amplified yeast display library into the yeast expression
vector. YVH10 yeast cells (provided by Prof. Dane Wittrup, Massachusetts Institute of Technology)
were used for expression of monoclonal antibodies. Yeast antibody expression was performed
following secretion protocols depicted in Wentz and Shusta [69] using SGT as induction media. Culture
supernatants were used directly as reagents in western blots.
4.6. ELISA Screening of Antibodies
ELISA was performed by coating 96-well ELISA plates (Nunc) with 10 ug/mL neutravidin diluted
in 1× phosphate-buffered saline (PBS), and incubating the plate overnight at 4 ◦C. Wells were blocked
with 2% MPBS (1× PBS, 2% skim milk (w/v)) and subsequently incubated with 300 nM biotinylated
mycolactone or ubiquitin as a negative control. After a rinse step, yeast undiluted supernatants
were added to the wells. After one-hour incubation at room temperature, a further rinse step was
performed, followed by HRP-conjugated anti-human Fc (Jackson ImmunoResearch, West Grove, PA,
USA) diluted 1:5000 in PBS and incubated 1 h at room temperature. After a final rinse step, the
immunocomplexes were revealed by adding TMB (Sigma-Aldrich, St. Louis, MO, USA) and reading
the plate at 450 nm. ELISA with non-biotinylated mycolactone and ubiquitin and LPS as negative
control was performed by directly coating 96-well ELISA plates (Nunc) with 300 nM of molecules
overnight at 4 ◦C. Wells were blocked with 2% MPBS (1× PBS, 2% skim milk (w/v)) and, after a washing
step, yeast undiluted supernatants were added to the wells and the ELISA completed following the
procedure described above.
4.7. Next-Generation Sequencing
The VH regions of the antibodies obtained after Selection 2 were amplified with specific primers
and submitted for Illumina MiSeq 2 × 250 bp sequencing (SeqMatic, Fremont, CA, USA). The CDR
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regions of these clones were identified using IgBlast. For HCDR3 analysis, in-house scripts were
developed using Python3.7. Levenshtein distance was calculated using the package ‘distance’ and
was normalized by the length of the smallest sequence. Sequences with less than 30% distance were
clustered. Principal component analysis was performed using the function implemented at the package
‘scikit-learn’.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/11/6/346/s1,
Table S1: List of HCDR3 clusters found after selection against mycolatone.
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